Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high estimate of $550.00, and a low estimate of $333.00. This current average reflects ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

Investors might want to bet on Alnylam Pharmaceuticals (ALNY), as earnings estimates for this company have been showing solid ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

UCSF has joined a growing network devoted to combating primary hyperoxaluria. As part of this initiative, patients can now ...

On May 2, Alnylam Pharmaceuticals reveals figures for the most recent quarter. Wall Street analysts expect Alnylam Pharmaceuticals will be reporting losses per share of $1.116.

Present Market Standing of Alnylam Pharmaceuticals With a volume of 918,360, the price of ALNY is up 1.19% at $257.76. RSI indicators hint that the underlying stock may be overbought.

Alnylam Pharmaceuticals's Current Market Status With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. RSI indicators hint that the underlying stock may be oversold.

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.